Cargando…
The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium
AIMS: We recently published that the positive inotropic response (PIR) to levosimendan can be fully accounted for by phosphodiesterase (PDE) inhibition in both failing human heart and normal rat heart. To determine if the PIR of the active metabolite OR-1896, an important mediator of the long-term c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349697/ https://www.ncbi.nlm.nih.gov/pubmed/25738589 http://dx.doi.org/10.1371/journal.pone.0115547 |
_version_ | 1782360065891631104 |
---|---|
author | Ørstavik, Øivind Manfra, Ornella Andressen, Kjetil Wessel Andersen, Geir Øystein Skomedal, Tor Osnes, Jan-Bjørn Levy, Finn Olav Krobert, Kurt Allen |
author_facet | Ørstavik, Øivind Manfra, Ornella Andressen, Kjetil Wessel Andersen, Geir Øystein Skomedal, Tor Osnes, Jan-Bjørn Levy, Finn Olav Krobert, Kurt Allen |
author_sort | Ørstavik, Øivind |
collection | PubMed |
description | AIMS: We recently published that the positive inotropic response (PIR) to levosimendan can be fully accounted for by phosphodiesterase (PDE) inhibition in both failing human heart and normal rat heart. To determine if the PIR of the active metabolite OR-1896, an important mediator of the long-term clinical effects of levosimendan, also results from PDE3 inhibition, we compared the effects of OR-1896, a representative Ca(2+) sensitizer EMD57033 (EMD), levosimendan and other PDE inhibitors. METHODS: Contractile force was measured in rat ventricular strips. PDE assay was conducted on rat ventricular homogenate. cAMP was measured using RII_epac FRET-based sensors. RESULTS: OR-1896 evoked a maximum PIR of 33±10% above basal at 1 μM. This response was amplified in the presence of the PDE4 inhibitor rolipram (89±14%) and absent in the presence of the PDE3 inhibitors cilostamide (0.5±5.3%) or milrinone (3.2±4.4%). The PIR was accompanied by a lusitropic response, and both were reversed by muscarinic receptor stimulation with carbachol and absent in the presence of β-AR blockade with timolol. OR-1896 inhibited PDE activity and increased cAMP levels at concentrations giving PIRs. OR-1896 did not sensitize the concentration-response relationship to extracellular Ca(2+). Levosimendan, OR-1896 and EMD all increased the sensitivity to β-AR stimulation. The combination of either EMD and levosimendan or EMD and OR-1896 further sensitized the response, indicating at least two different mechanisms responsible for the sensitization. Only EMD sensitized the α(1)-AR response. CONCLUSION: The observed PIR to OR-1896 in rat ventricular strips is mediated through PDE3 inhibition, enhancing cAMP-mediated effects. These results further reinforce our previous finding that Ca(2+) sensitization does not play a significant role in the inotropic (and lusitropic) effect of levosimendan, nor of its main metabolite OR-1896. |
format | Online Article Text |
id | pubmed-4349697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-43496972015-03-17 The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium Ørstavik, Øivind Manfra, Ornella Andressen, Kjetil Wessel Andersen, Geir Øystein Skomedal, Tor Osnes, Jan-Bjørn Levy, Finn Olav Krobert, Kurt Allen PLoS One Research Article AIMS: We recently published that the positive inotropic response (PIR) to levosimendan can be fully accounted for by phosphodiesterase (PDE) inhibition in both failing human heart and normal rat heart. To determine if the PIR of the active metabolite OR-1896, an important mediator of the long-term clinical effects of levosimendan, also results from PDE3 inhibition, we compared the effects of OR-1896, a representative Ca(2+) sensitizer EMD57033 (EMD), levosimendan and other PDE inhibitors. METHODS: Contractile force was measured in rat ventricular strips. PDE assay was conducted on rat ventricular homogenate. cAMP was measured using RII_epac FRET-based sensors. RESULTS: OR-1896 evoked a maximum PIR of 33±10% above basal at 1 μM. This response was amplified in the presence of the PDE4 inhibitor rolipram (89±14%) and absent in the presence of the PDE3 inhibitors cilostamide (0.5±5.3%) or milrinone (3.2±4.4%). The PIR was accompanied by a lusitropic response, and both were reversed by muscarinic receptor stimulation with carbachol and absent in the presence of β-AR blockade with timolol. OR-1896 inhibited PDE activity and increased cAMP levels at concentrations giving PIRs. OR-1896 did not sensitize the concentration-response relationship to extracellular Ca(2+). Levosimendan, OR-1896 and EMD all increased the sensitivity to β-AR stimulation. The combination of either EMD and levosimendan or EMD and OR-1896 further sensitized the response, indicating at least two different mechanisms responsible for the sensitization. Only EMD sensitized the α(1)-AR response. CONCLUSION: The observed PIR to OR-1896 in rat ventricular strips is mediated through PDE3 inhibition, enhancing cAMP-mediated effects. These results further reinforce our previous finding that Ca(2+) sensitization does not play a significant role in the inotropic (and lusitropic) effect of levosimendan, nor of its main metabolite OR-1896. Public Library of Science 2015-03-04 /pmc/articles/PMC4349697/ /pubmed/25738589 http://dx.doi.org/10.1371/journal.pone.0115547 Text en © 2015 Ørstavik et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Ørstavik, Øivind Manfra, Ornella Andressen, Kjetil Wessel Andersen, Geir Øystein Skomedal, Tor Osnes, Jan-Bjørn Levy, Finn Olav Krobert, Kurt Allen The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium |
title | The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium |
title_full | The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium |
title_fullStr | The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium |
title_full_unstemmed | The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium |
title_short | The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium |
title_sort | inotropic effect of the active metabolite of levosimendan, or-1896, is mediated through inhibition of pde3 in rat ventricular myocardium |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349697/ https://www.ncbi.nlm.nih.gov/pubmed/25738589 http://dx.doi.org/10.1371/journal.pone.0115547 |
work_keys_str_mv | AT ørstavikøivind theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT manfraornella theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT andressenkjetilwessel theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT andersengeirøystein theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT skomedaltor theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT osnesjanbjørn theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT levyfinnolav theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT krobertkurtallen theinotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT ørstavikøivind inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT manfraornella inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT andressenkjetilwessel inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT andersengeirøystein inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT skomedaltor inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT osnesjanbjørn inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT levyfinnolav inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium AT krobertkurtallen inotropiceffectoftheactivemetaboliteoflevosimendanor1896ismediatedthroughinhibitionofpde3inratventricularmyocardium |